Inhibikase Therapeutics Stock (NASDAQ: IKT) stock price, news, charts, stock research, profile.
You can purchase shares of Inhibikase Therapeutics (NASDAQ:IKT) through any online brokerage.
Other companies in Inhibikase Therapeutics’s space includes: Outlook Therapeutics (NASDAQ:OTLK), Innate Pharma (NASDAQ:IPHA), Skye Bioscience (NASDAQ:SKYE), Cabaletta Bio (NASDAQ:CABA) and Adverum Biotechnologies (NASDAQ:ADVM).
Inhibikase Therapeutics has a consensus price target of $6.50.
The stock price for Inhibikase Therapeutics (NASDAQ: IKT) is $2.01 last updated November 21, 2024 at 4:00 PM EST.
There are no upcoming dividends for Inhibikase Therapeutics.
Inhibikase Therapeutics’s Q3 earnings are confirmed for Thursday, November 14, 2024.
There is no upcoming split for Inhibikase Therapeutics.
Inhibikase Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.